FORZA trial

a randomized trial of Fractional flow reserve vs Optical coherence tomography to guide RevasculariZAtion of intermediate coronary stenoses

Francesco Burzotta & Antonio Maria Leone

INSTITUTE OF CARDIOLOGY
Fondazione Policlinico Universitario A. Gemelli IRCCS,
Università Cattolica del Sacro Cuore
Rome, Italy

Disclosure Statement of Financial Interest

Within the past 12 months, I received speaker fees from Abbott, Medtronic and Abiomed

WHY THIS TRIAL ?



Stenosis
<40%

Stenosis
>80%





Stenosis
40-80%

?

WHY THIS TRIAL ?





Stenosis 40-80%

angiographically intermediate coronary lesions

WHY THIS TRIAL ?



Stenosis
40-80%

angiographically
intermediate
coronary lesions

FORZA STUDY DESIGN



FORZA STUDY DESIGN

350 patients with (one or more) angiographically intermediate coronary stenosis

1:1 RANDOMIZATION

FFR-GUIDANCE

OCT-GUIDANCE

CLINICAL FOLLOW-UP @ 13 MONTH

Costs, Angina status (evaluated by a validated questionnaire), major adverse cardiac events (MACE)

Predefined primary combined endpoint

MACE or significant residual angina @ 13 months

PRIMARY STUDY END-POINT: MACE OR SIGNIFICANT ANGINA @13 MONTHS



PRIMARY END-POINT COMPONENTS (@13 MONTHS)



ESTIMATED MEAN COST PER PATIENT (@13 MONTHS)



TAKE HOME MESSAGES

-first trial comparing **OCT** vs. **FFR** in patients with coronary artery disease

-the selection of **OCT** is safe, causes initially higher number of PCIs, but is associated with lower occurrence of the combined endpoint of MACE or significant angina after 13 months

-the selection of **FFR** is associated with higher rate of medically managed patients and lower costs up to 13 months

Gemelli
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Università Cattolica del Sacro Cuore

THANK YOU FOR KIND ATTENTION !!!

UCSC Interventional Cardiology

JACC
Cardiovascular Interventions

IN PRESS